Stem cells in drug discovery, regenerative medicine and cancer by Rountree, C Bart
The Stem Cell World Congress brought together scholars 
and  experts  from  a  wide  array  of  stem  cell  research. 
Discussions  covered  a  range  of  issues  and  topics, 
including basic science discoveries related to the use of 
neural progenitors and mesenchymal stem cells (MSCs) 
for the treatment of neurodegenerative disease, the legal 
aspects  related  to  patent  protection  of  stem-cell-based 
discoveries,  the  best  practices  for  biobanking  of  cord 
blood, and the ethical considerations related to stem cell 
research.  This  report  focuses  on  major  themes  of  the 
meeting,  with  a  focus  on  the  stem  cell  topics  related 
specifically to medical genomics.
Stem cells in regenerative medicine
One of the primary focuses of the meeting was the use of 
stem-cell-based therapy in regenerative medicine, which 
aims to regenerate damaged tissues. Keynote presenta-
tions discussed research in the field of neurodegenerative 
diseases, such as Alzheimer’s disease, Huntington’s disease, 
and amyotrophic lateral sclerosis. Jan Nolta (University 
of  California  Davis,  Sacramento,  USA)  suggested  that 
stem cell therapy for neurodegenerative diseases repre-
sents  a  potential  cure,  compared  with  small-molecule-
based therapy, which can ameliorate symptoms but not 
correct underlying genetic or structural problems. Nolta 
focused on Huntington’s disease, an autosomal dominant 
disease that is linked to increased CAG repeats in the 
Huntington gene (HTT) on chromosome 4. Nolta is using 
a  catheter-based  approach  to  deliver  bone-marrow-
derived MSCs, which are programmed to secrete a small 
interfering  RNA  to  downregulate  mutant  Htt  protein. 
She has found that MSCs home to sites of injury within 
the brain, have a ‘neuro-protective effect’, and can reverse 
injury  through  Htt  downregulation.  The  MSCs  do  not 
form  tumors,  even  8  months  after  transplant  into 
immune-deficient animals. Risk of tumor is one of the 
concerns in using human embryonic stem (hES) cells for 
regenerative medicine.
Larry  Goldstein  (University  of  California  San  Diego, 
USA) discussed the idea of using stem cells to model the 
genomic variation that is a contributor to human neuro-
degenerative disease. He said that developing cell-based 
therapies  is  critical  for  neurodegenerative  diseases 
because 50% of the population over 85 years of age will 
develop Alzheimer’s disease. He discussed using human 
induced  pluripotent  stem  (iPS)  cells  derived  from  the 
fibroblasts  of  people  with  both  sporadic  and  familial 
forms of Alzheimer’s disease to identify genotype-pheno-
type  correlation  within  the  biochemical  derangements 
typically  observed  in  neurodegenerative  disease.  In 
addition, he presented the pre-clinical development of a 
cell-based therapy for amyotrophic lateral sclerosis using 
the H9 hES cell line differentiated into neural progenitors 
and astrocyte-like cells.
For  the  treatment  of  stroke  patients,  Marcel  Daadi 
(Stanford University, Palo Alto, USA) presented the use 
of  hES  cell  therapy  to  aid  in  motor  function  recovery. 
Neural progenitor cells derived from hES cells partially 
rescued the neurological deficits in experimental stroke 
animal models, specifically in the areas of strength, co-
ordination,  balance  and  other  motor  functions.  Daadi 
showed that in vivo molecular imaging using functional 
magnetic  resonance  imaging  (MRI)  allows  tracking  of 
hES-cell-derived  neural  progenitors  to  the  source  of  a 
brain injury.
Suzanne  Berry  (University  of  Illinois,  Champaign, 
USA) presented work related to mesoangioblasts isolated 
from murine fetal aortic arch. Mesoangioblasts can differ-
entiate into smooth muscle, skeletal muscle, and cardiac 
muscle.  Berry  used  a  Duchene  muscular  dystrophy 
mouse  model  system  to  show  that  mesoangioblasts 
incorporate  into  skeletal  muscle  to  restore  dystrophin 
protein  levels.  In  addition,  mesoangioblasts  can  differ-
entiate into cardiac muscle in vivo and improve cardiac 
Abstract
A report on the Stem Cells World Congress held in San 
Diego, USA, 24-25 January 2011.
© 2010 BioMed Central Ltd





Penn State College of Medicine and Hershey Medical Center, 500 University Drive, 
H085, Hershey, 17033, USA
Rountree Genome Medicine 2011, 3:15 
http://genomemedicine.com/content/3/3/15
© 2011 BioMed Central Ltdfunction, as measured by echocardiogram, in this model 
system.
Stem cells in drug discovery
Joseph  Frank  (National  Institutes  of  Health  Clinical 
Center,  Bethesda,  USA)  discussed  the  concept  of  cell 
tracking in cell-based therapies and described cell track-
ing as a ‘key issue’ for the US Food and Drug Adminis-
tration in terms of approval for stem-cell-based therapies. 
Frank described cell-based therapies on a ‘micromolar’ 
scale given the number of cells injected compared with 
target organ cell mass. He used iron labeling in vitro to 
show the retention of 99% of the labeled iron in human 
hematopoietic stem cells. Iron-labeled cells can be identi-
fied using standard MRI protocols and can be followed 
for  up  to  6  months  in  vivo,  and  iron  does  not  induce 
differentiation in stem cells. He presented a novel therapy 
adjunct in which a magnet is used to ‘home’ iron-labeled 
cells  to  a  specific  site  in  vivo  using  focused  magnetic 
fields.  In  addition,  he  highlighted  that  pulsed,  focused 
ultrasound improves local retention of stem cells.
Hakim  Djabalah  (Memorial  Sloan-Kettering  Cancer 
Center,  New  York,  USA)  presented  work  on  a  high-
through  put  drug  discovery  screen  to  identify  small-
molecule inhibitors and drivers of differentiation in hES 
cells. He said that given the complexity and difficulty of 
hES cell work, this strategy was not likely to yield signi-
ficant  targets  in  a  cost-effective  manner  using  current 
technology.  Djabalah  also  presented  preliminary  data 
showing that iPS cells provide a more stable platform for 
drug discovery in terms of target identification and valida-
tion for both inhibitors and drivers of differ  entiation.
Stefan Jellbaur (University of California, Irvine, USA) 
and  Enal  Razvi  (Select  Biosciences,  Sudbury,  UK) 
presented a market analysis of stem-cell-based therapies 
and cancer stem cell research. One key issue related to 
stem cell research is that the most common hES cell lines 
published, the H1 and H9 lines, would be required for 
any study using a novel hES cell line to provide a known 
standard against which new lines can be validated.
Stem cells in inflammation and cancer
Joni Ylostalo (Texan A&M Health Science Center, College 
Station,  USA)  presented  a  novel  culture  method  for 
human  MSCs  using  a  ‘hanging  drop’  system  of  cell 
suspension.  In  this  suspension  system,  MSCs  form 
spheroids,  and  these  show  a  potent  anti-inflammatory 
response  (as  measured  by  production  of  prostaglandin 
E2) compared with MSCs that are adherent to plastic in a 
standard culture system.
Mauricio Rojas (University of Pittsburgh, USA) showed 
that  the  anti-inflammatory  response  of  MSCs  can  be 
used to prevent acute and chronic lung injury if the cells 
are  used  early  in  the  injury  cycle.  Using  a  murine 
heterotrophic allogenic trachea transplant system, MSCs 
reduce  obliterative  bronchiolitis,  a  disease  of  chronic 
rejection that is a significant problem in lung transplant 
patients.
I presented work supporting the hypothesis that a stem 
cell  phenotype  is  produced  after  the  epithelial-to-
mesenchymal  transition  in  liver  cancer.  These  findings 
are similar to recent discoveries in the breast cancer field, 
where the epithelial-to-mesenchymal transition has been 
shown to generate cancer stem cells.
Conclusions
The  2011  Stem  Cell  World  Congress  covered  a  wide 
range  of  topics  related  to  stem-cell-based  therapy  and 
discovery. Many of the presentations related to regenera-
tive  medicine  focused  on  neurodegenerative  diseases. 
One suggestion was that neuronal progenitors represent 
a  potential  default  pathway  of  differentiation  for  hES 
cells.  Critical  barriers  to  successful  implementation  of 
stem-cell-based  therapy  for  regenerative  medicine 
include  documentation  of  cell  tracking  studies  during 
pre-clinical  trials.  Adult  stem  cells,  such  as  MSCs,  are 
being evaluated for their anti-inflammatory effect and as 
potential  delivery  vehicles  for  cell-based  gene  therapy. 
Lastly,  iPS  cells  derived  from  patients  with  genetic 
diseases  will  provide  a  unique  opportunity  to  explore 
genotype-phenotype  correlation  and  may  ultimately  be 
used to validate genome-wide association studies.
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